Background {#Sec1}
==========

Hepatitis E virus (HEV) was first identified in 1983. It causes sporadic cases of hepatitis or outbreaks and the disease is generally self-limited although it may cause fulminant hepatitis in pregnant women, elderly, those with underlying chronic hepatitis, immunosuppressed, and transplant recipients \[[@CR1], [@CR2]\]. It is a non-enveloped single stranded RNA virus in the genus *Hepevirus* and the family Hepeviridae. It has four genotypes. Genotypes 1 and 2 cause disease in humans while genotypes 3 and 4 cause diseases both in humans and animals especially in pigs \[[@CR3]\]. HEV can be transmitted waterborne, foodborne, or zoonotic. While fecal--oral route is common in the countries where HEV is endemic, in developing countries, zoonotic transmission is more prevalent and causes sporadic infections \[[@CR4], [@CR5]\]. Seroprevalence differs according to the way of transmission. According to World Health Organization (WHO), 20 million HEV infections develop every year, 15% of them being symptomatic \[[@CR6]\].

Turkey is a developing country; annual income is 25,275 US\$/capita, with a population of 77 million, surface area of 783.563 km^2^ and with 62.5% agricultural land \[[@CR7]\]. Viral hepatitis is a challenging health problem with a significant morbidity. Hepatitis seroprevalence differs among regions probably due to the socio-economical differences. HBV and HCV prevalences are 4 and 1% respectively \[[@CR8]\]. Hepatitis D represents another considerable hepatitis etiology with a prevalence of 5--27% \[[@CR9]\].

Hepatitis A and hepatitis E are endemic in the country. The first study reported HEV seroprevalence as 5.9% in 1993 \[[@CR10]\]. Limited number of epidemiological studies was published after that preliminary study. In this systematic review, we aimed to analyze HEV studies reported from Turkey, to determine the current situation of the disease in the country, to delineate the limits of the studies and to determine the future study areas.

Methods {#Sec2}
=======

This systematic review was prepared according to the guideline of preparation and report of systematic review (PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses) \[[@CR11]\]. Three main health and biomedical databases of Pubmed, Scopus, and Science Citation Index (SCI) were used for the literature search. Since HEV was discovered in 1983 \[[@CR1]\], the search period was taken as 1980 to June 2017.

The search was done using the terms of "Hepatitis E, hepatitis E virus, Turkey, Turkiye, Travel migrant" in the three databases in order to determine all publications about HEV from Turkey. The language was not restricted on the search. Duplicate publications, those not including HEV and/or Turkey, reviews and meeting abstracts were excluded. The result was recorded in Endnote program. Diagrams were produced according to the PRISMA guideline.

Data analysis {#Sec3}
-------------

Study date, publication date, authors, type of study, study field, sample size, and age groups were identified and presented as tables.

Results {#Sec4}
=======

The results of literature search were shown in flow diagram (Fig. [1](#Fig1){ref-type="fig"}). A total of 285 publications were identified in the databases; after removing duplicates, the abstracts of remaining 207 publications were further studied. Forty-six publications met the inclusion criteria. Another nine studies were noted not meeting the inclusion criteria after searching full texts and were excluded.Fig. 1Flow diagram for literature search

Among the remaining studies, one was a case report and another one investigated cupper level in patients with hepatitis including HEV. Twenty-eight publications were the seroprevalence studies in Turkey. Fifteen of these studies were in general population (Table [1](#Tab1){ref-type="table"}), and 13 in specific groups: those with underlying disorders (n = 5), in patients presenting with acute hepatitis (n = 3), in pregnant women (n = 2), in those working in risky occupations (n = 2) and in those residing in the camps (n = 1) (Table [2](#Tab2){ref-type="table"}).Table 1HEV seroprevalence studies in TurkeyAuthors, referencesYear publishedYearCityStudy typeSample sizePrevalence (IgG) (%)Prevalence by age groupPower of studyRemarksAribas et al. \[[@CR12]\]2000NAKonyaC-S16212.3NAChildren admitted to hospitalAtabek et al. \[[@CR13]\]20042001--2002KonyaC-S2105.71--6 year: 0, 7--12 year: 6.8%, 13--18 year: 8.9%NARural 8.5%, urban 0.2%, p \> 0.05Aydın et al. \[[@CR14]\]20152012--2013AnkaraC-S10434.40--18 year: 0, 19--55 year: 30.4%, 56--90 year: 69.5%NABayhan et al. \[[@CR15]\]20162014VanC-S4084.24.4% in 0--5 year, 3.4% in 6--13 year, 5.7% in 14--18 yearCalculatedIndividuals admitting to hospital were compared in age groups: no difference.Cesur et al. \[[@CR16]\]20022000--2001AnkaraC-S10463.815--30 year: 0, 30--45 year: 4.4%, 45--60 year: 6.6%, \> 60 year: 7.4%NA15--75 year age group admitting to hospitalCevahir et al. \[[@CR17]\]2013NADenizliC-S18512.47 year: 18.1%, 14 year: 6.6%NARural %13.1 vs. urban %11.7, p \> 0.05. 7 year had higher prevalence than 6 year groupColak et al. \[[@CR18]\]20021996--1997AntalyaC-S3380.91--5 year: 0, 6--11 year: 1.6%NANo seropositives in preschool childrenEker et al. \[[@CR19]\]20092005EdirneC-S5822.4CalculatedNo difference in subgroups. Age range was not providedKaya et al. \[[@CR20]\]20082003DüzceC-S5890.36 month--12 year: 0, 13--17 year: 0.8%NANo seropositives in \< 13 year-oldMaral et al. \[[@CR21]\]20092003--2005AnkaraL5151.7--2.1NA6--14 year group. Same group re-studied 2 years laterOlcay et al. \[[@CR22]\]20032000Ankara, Manisa, DiyarbakirC-S9106.37--14 year: 1.6%, 15--24 year: 3.3%, 25--64 year: 8.2%, \> 64 year: 10%NAAnkara 2.7%, Manisa 3.8%, Diyarbakir  %11.7, significant. In Diyarbakir prevalence increased by ageSidal et al. \[[@CR23]\]20011997--1998IstanbulC-S9092.16 month--2 year: 4.8%, 2--5 year: 3.1%, 5--10 year: 2.1%, 10--16 year: 0.3%NAThomas et al. \[[@CR10]\]19931990--1992Istanbul, Aydin, Ayvalik, Adana, TrabzonC-S13505.911--20 year: 0, 21--30 year: 3.7%, 31--40 year: 9.1%, 41--50 year: 5.7%, 51--60 year: 8.7%, 61--70 year: 6.9%, 71--80 year: 11.1%NAOlder age, HCV, being in Adana city were determined as risk factorsYuce et al. \[[@CR24]\]1998NAAnkaraC-S40000 month--17 year: 0NA*C-S* Cross-sectional, *L* longitudinal, *y* years old, *m* months old, *NA* not available Table 2HEV seroprevalence in special groupsAuthors, referencesYear publishedYearCityStudy typeTarget populationSample sizePrevalenceCG sample sizeCG prevalence (IgG) (%)Power of studyRemarksAksu et al. \[[@CR25]\]19991996--1998İzmirC-SBehcet's disease1247%518NAp \> 0.05Atabek et al. \[[@CR26]\]2003NAKonyaC-SDiabetic children636.3%637.9NAp \> 0.05Aydin et al. \[[@CR27]\]2016NAErzurumC-SAnimal workers10335.9%924.4NAp \< 0.05. Most frequent in animal husbandry, poultry. No seropositivity in veterinariesBayram et al. \[[@CR28]\]20072004GaziantepC-SAdult CHB and CHC364CHB: 13.7%, CHC: 54%. HEV RNA (+); CHB: 14.7%, CHC: 54.6%17815.7NAHEV higher in CHC patients (p \< 0.05), speculated that HCV and HEV may share the same way of transmissionCengiz et al. \[[@CR29]\]1996NASamsunC-SAdult HD patients7213.9%555.5NAp \< 0.05Cevrioglu et al. \[[@CR30]\]20042000--2002AfyonC-SPregnant women24512.6%7611.8NAp \> 0.05Ceylan et al. \[[@CR31]\]2003NADiyarbakirC-SAgricultural workers4634.8%454.4NAp \< 0.05Coursaget et al. \[[@CR32]\]1993NAIstanbulC-SAcute non-A non-B non-C hepatitis1811%NANAProbable prevalence 1--2%. Letter to a studyKoksal et al. \[[@CR33]\]19941991--1992DiyarbakirC-SAcute non-A non-B hepatitis5373.3%1000NAOncu et al. \[[@CR34]\]2006NAAydinC-SPregnant women3867%NANALow prevalence in high-educatedSencan et al. \[[@CR35]\]20041999DuzceC-SChildren post-earthquake camps4764.7--17.2%NANADuzce and Golyaka camps have significantly different rates attributed to being the first camp just after the earthquake with lower sanitation statusUçar et al. \[[@CR36]\]2009NAHatayC-SAdults HD patients9220.6%NANAYayli et al. \[[@CR37]\]2002NAIspartaC-SChildren3409%NANA5--16 age range. After a hepatitis outbreak in the village, some children had symptoms and higher ALT*CG* Control group, *C-S* cross-sectional, *NA* not available, *CHB* chronic hepatitis B, *CHC* chronic hepatitis C, *HD* hemodialysis

For the remaining six studies, two were seroprevalence studies including Turkish immigrants in Italy and the Netherlands (Table [3](#Tab3){ref-type="table"}), and four were acute HEV infection case reports developing after travel to Turkey. The cities in which the studies were performed are given in Fig. [2](#Fig2){ref-type="fig"}.Table 3HEV infection prevalence in migrantsAuthors, referenceYearCountryStudy typeTarget populationSample sizePrevalence (IgG) (%)PowerRemarksChironna et al. \[[@CR38]\]2000ItalyCross sectionalAdults36810.3NAImmigrants from Turkey. No seropositives in 0--10 year-old groupSadik et al. \[[@CR39]\]2004NetherlandsCross sectionalAdults29633.4NASeroprevalence is similar to that in Dutch population*NA* not available Fig. 2Distribution of the studies. Colors represent number of studies (total number of sites are more than actual study numbers because some studies were done in more than one city)

Hepatitis E virus seroprevalence ranges from 0 to 12.4% among healthy individuals (Table [1](#Tab1){ref-type="table"}). The prevalence was determined as 7--8% in pregnant women, 13% in chronic HBV patients, 54% in chronic HCV patients, 13.9--20.6% in patients with chronic renal failure, and ≈ 35% in agriculture workers (Table [2](#Tab2){ref-type="table"}).

Among individuals immigrating form Turkey to Europe, HEV seroprevalence was found 10.3% in Italy \[[@CR38]\] and 33.4% in the Netherlands (Table [3](#Tab3){ref-type="table"}) \[[@CR39]\]. Four patients were reported with a travel history to Turkey \[from Germany (n = 1), Sweden (n = 1), and UK (n = 2)\] and one died of HEV fulminant hepatitis \[[@CR40]--[@CR43]\].

Discussion {#Sec5}
==========

No any outbreaks of HEV have been reported from Turkey so far. The seroprevalence of HEV depends on the region, age group, and study population. Using different ELISA kits in the diagnosis may have a role since the sensitivities of the ELISA kits are different \[[@CR44], [@CR45]\].

The studies were performed mainly in the big cities of Ankara and Istanbul and the study populations included blood donors and patient admitting to the hospitals with a reason other than hepatitis. For that reason, the studies give a general idea about the seroprevalence and may not provide realistic information. HEV seroprevalence is lower in children than in adults and the children lack antibodies. HEV seroprevalence is low, even zero in some pediatric series although HAV seroprevalence, another fecal--oral transmitted virus is high \[[@CR10], [@CR14], [@CR18], [@CR20], [@CR22]\].

Similarly, a systematic review of HEV infection in children reported the seroprevalence as \< 10% in children younger than 10-year old \[[@CR46]\]. No change was detected in the seroprevalence in these children by time \[[@CR13]\]. No any difference was detected in HEV seroprevalence in children living rural or urban areas \[[@CR13], [@CR17]\]. These results suggest that fecal route is not a main way of transmission or HEV transmission is low due to low fecal secretion and its low infectivity rate.

Hepatitis E virus seroprevalence increases by age in Turkey. It is higher in 3rd--4th decades and older age was determined as an independent risk factor for HEV seropositivity in a meta-analysis \[[@CR10]\]. HEV seroprevalence differ according to the regions; being highest in the Southeastern Anatolia region and lowest in the western parts of the country \[[@CR22]\].

Low socio-economical status may be associated with the higher seroprevalence. Seroprevalence is higher than the general population in those staying camps \[[@CR35]\], working in agriculture and animal husbandry \[[@CR31]\] those with chronic blood-borne infections of HBV and HCV \[[@CR28]\], and patients with chronic renal failure given transfusions \[[@CR29], [@CR36]\] suggesting that more than one way of transmission may be effective.

Any study about HEV in water sources was not found in the databases. A doctoral thesis reported HEV-RNA positivity by RT-PCR in 3 out of 150 samples (drinking water, well water, swimming pool, sea water, river water, and sewage) from differing parts of the country \[[@CR47]\]. This finding suggests a lower rate of transmission through water sources. There is a need for multi-center, well-planned epidemiologic studies searching HEV seroprevalence, ways of transmission, and risk factors in Turkey.

Turkey has been included in the endemic countries for HEV depending on two studies conducted in eastern and western parts of the country 24 years ago and far from reflecting the real situation. The seroprevalence of HEV is not exactly determined although acute hepatitis E is a reportable disease. This may be due to not using the HEV diagnostic tests commonly.

Hepatitis E virus infection may cause fulminant hepatitis and death. Turkey is among the first 10 countries of highest organ transplantation incidence in Europe (39.3 and 16.7/1 million population for kidney and liver respectively) \[[@CR48]\]. However HEV prevalence is not known in transplanted patients or in immunosuppressed. Among individuals immigrate from Turkey to Europe; in the Netherlands, HEV seroprevalence was similar to that of the autochthonous Dutch population and another study found higher prevalence in immigrants coming from Turkey. HEV infection may challenge the immunosuppressed and those with underlying disorders especially when they travel to endemic regions. Four patients travelled to Turkey have been reported in the medical literature. Genotype 3 was detected in one case suggesting a food-borne transmission. Current data show that HEV infection related to travel to Turkey is low.

In conclusion; current review gives detailed information about HEV infection in Turkey. Previous studies suggest that Turkey is among the endemic countries of HEV. However, there are some pitfalls for the analysis of data: the studies are not powered enough to represent the whole population; they did not include immunosuppressed patients and solid organ recipients; and the prevalence of non-A non-B hepatitis was not determined. There is a need for well-designed epidemiological studies to determine HEV seroprevalence, ways of transmission, and risk factors.
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